In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model | Zendy

YuFeng Zhou | Zendy; Ping Liu | Zendy; Shu-He Dai | Zendy; Jian Sun | Zendy; Ya-Hong Liu | Zendy; XiaoPing Liao | Zendy

Open Access

In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model

Author(s) -

YuFeng Zhou,

Ping Liu,

Shu-He Dai,

Jian Sun,

Ya-Hong Liu,

XiaoPing Liao

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01354-20

Subject(s) - streptococcus pneumoniae , staphylococcus aureus , in vivo , microbiology and biotechnology , pneumonia , pharmacodynamics , antibiotics , staphylococcal infections , methicillin resistant staphylococcus aureus , medicine , antibacterial agent , biology , bacteria , pharmacology , pharmacokinetics , genetics

We determined in vivo efficacy and target PK/PD exposures of antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in the murine pneumonia model. The mean plasma free drug area under the concentration-time curve/MIC ( f AUC/MIC) targets associated with stasis and 1-log 10 and 2-log 10 kill effects were 8.93, 19.2, and 48.1, respectively, for S. pneumoniae , whereas they were 30.5, 55.4, and 115.8, respectively, for S. aureus The f AUC/MIC targets in murine lung epithelial lining fluids (ELF) for the same endpoints were nearly 2-fold higher than those in plasma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research